阿格列汀在2型糖尿病治疗中的研究进展  

Research progress of alogliptin in treatment of type 2 diabetes mellitus

作　　者：周岩[1] 姬秋和[2] 

机构地区：[1]解放军第451医院内分泌科,西安710054 [2]第四军医大学附属西京医院内分泌科,西安710032

出　　处：《中华内分泌代谢杂志》2014年第10期868-871,共4页Chinese Journal of Endocrinology and Metabolism

摘　　要：阿格列汀是近年上市的新型二肽基肽酶-4抑制剂.大量临床研究表明阿格列汀单药治疗、联合其他口服降糖药物或胰岛素治疗,都能有效地控制2型糖尿病患者血糖.阿格列汀每日12.5 mg或25 mg单药治疗可降低HbA1C达0.56％ ～ 0.59％,与其它降糖药联用可进一步降低HbA1c达0.4％～0.8％.患者耐受性佳,低血糖事件发生率低,并且不增加体重;对于合并心血管疾病的患者不增加心血管风险.Alogliptin is a novel dipeptide peptidase-4 inhibitor approved for the treatment of type 2 diabetic mellitus.Numerous clinical studies showed that alogliptin alone or in combination with other oral antidiabetic drugs or insulin can substantially control the level of plasma glucose and glycated hemoglobin （HbA1c） in type 2 diabetic patients.12.5 to 25 mg alogliptin alone once daily reduced HbA1c by 0.56％ to 0.59％ ; while combination with other antidiabetic agents resulted additional HbA1c lowering of 0.4％ to 0.8％.Alogliptin was well tolerated,with low incidence of hypoglycemia and no weight gain.Furthermore,alogliptin displayed no extra cardiovascular risk in patients with cardiovascular diseases.

关 键 词：糖尿病 2型 二肽基肽酶-4抑制剂 阿格列汀 

分 类 号：R587.1[医药卫生—内分泌]